|
1
|
Cauchi S, Van Venetien F, Sciberras M and
Ellul P: Colitis trouble up high: a case of gastroduodenal
ulcerative colitis and literature review. J Gastrointestin Liver
Dis. 34:128–132. 2025.PubMed/NCBI View Article : Google Scholar
|
|
2
|
Ruan G, Sun Y, Yu Z, Bai X, Yang H and
Qian J: Global, regional, and national burden of inflammatory bowel
disease from 1990 to 2021: Findings from the global burden of
disease 2021. Gastroenterol Rep (Oxf). 13(goaf082)2025.PubMed/NCBI View Article : Google Scholar
|
|
3
|
Wu Y, He S, Cao M, Teng Y, Li Q, Tan N,
Wang J, Zuo T, Li T, Zheng Y, et al: Comparative analysis of cancer
statistics in China and the United States in 2024. Chin Med J
(Engl). 137:3093–3100. 2024.PubMed/NCBI View Article : Google Scholar
|
|
4
|
Harpaz N and Polydorides AD: Upper
gastrointestinal manifestations of inflammatory bowel disease. Surg
Pathol Clin. 13:413–430. 2020.PubMed/NCBI View Article : Google Scholar
|
|
5
|
Katsandegwaza B, Horsnell W and Smith K:
Inflammatory bowel disease:A review of pre-clinical murine models
of human disease. Int J Mol Sci. 23(9344)2022.PubMed/NCBI View Article : Google Scholar
|
|
6
|
Chen B, Dong X, Zhang JL, Sun X, Zhou L,
Zhao K, Deng H and Sun Z: Natural compounds target programmed cell
death (PCD) signaling mechanism to treat ulcerative colitis: A
review. Front Pharmaco. l15(1333657)2024.PubMed/NCBI View Article : Google Scholar
|
|
7
|
Shen P, Deng X, Chen Z, Ba X, Qin K, Huang
Y, Huang Y, Li T, Yan J and Tu S: SIRT1: A potential therapeutic
target in autoimmune diseases. Front Immunol.
12(779177)2021.PubMed/NCBI View Article : Google Scholar
|
|
8
|
Mir AR, Moinuddin and Islam S:
Circulating autoantibodies in cancer patients have high specificity
for glycoxidation modified histone H2A. Clin Chim Acta. 453:48–55.
2016.PubMed/NCBI View Article : Google Scholar
|
|
9
|
Jia X, Liu H, Ren X, Li P, Song R and Li
X, Guo Y and Li X: Nucleolar protein NOC4L inhibits tumorigenesis
and progression by attenuating SIRT1-mediated p53 deacetylation.
Oncogene. 41:4474–4484. 2022.PubMed/NCBI View Article : Google Scholar
|
|
10
|
Barjasteh AH, Al-Asady AM, Latifi H, Al
Okla S, Al-Nazwani N, Avan A, Khazaei M, Ryzhikov M, Nadi-Yazdi H
and Hassanian SM: Maximizing treatment options for IBD through drug
repurposing. Curr Pharm Des. 30:2538–2549. 2024.PubMed/NCBI View Article : Google Scholar
|
|
11
|
Zhang Y, Wang S, Dai M, Nai J, Zhu L and
Sheng H: Solubility and bioavailability enhancement of oridonin: A
review. Molecules. 25(332)2020.PubMed/NCBI View Article : Google Scholar
|
|
12
|
Li X, Zhang C, Ma W, Xie X and Huang Q:
Oridonin: A review of its pharmacology, pharmacokinetics and
toxicity. Front Pharmacol. 12(645824)2021.PubMed/NCBI View Article : Google Scholar
|
|
13
|
Wang M, Xu B, Liu L and Wang D: Oridonin
attenuates dextran sulfate sodium-induced ulcerative colitis in
mice via the Sirt1/NF-κB/p53 pathway. Mol Med Rep. 26(312)2022.
|
|
14
|
Tu J, Xu Y, Xu J, Ling Y and Cai Y:
Chitosan nanoparticles reduce LPS-induced inflammatory reaction via
inhibition of NF-κB pathway in Caco-2 cells. Int J Biol Macromol.
86:848–856. 2016.PubMed/NCBI View Article : Google Scholar
|
|
15
|
Chen M, Chen C, Gao Y, Li D, Huang D, Chen
Z, Zhao X, Huang Q, Wu D, Lai T, et al: Bergenin-activated SIRT1
inhibits TNF-α-induced proinflammatory response by blocking the
NF-κB signaling pathway. Pulm Pharmacol Ther.
62(101921)2020.PubMed/NCBI View Article : Google Scholar
|
|
16
|
Ban J, Peng X, Zhang Y, Liu Y, Wei Y, Ao
L, Tian H, He X, Zhao H and Li J: Oridonin alleviates SiNPs-induced
pulmonary fibrosis by inhibiting pyroptosis via IRE1α-XBP1s-NLRP3
pathway. Int Immunopharmacol. 164(115388)2025.PubMed/NCBI View Article : Google Scholar
|
|
17
|
Shao YY, Guo Y, Feng XJ, Liu JJ, Chang ZP,
Deng GF, Xu D, Gao JP and Hou RG: Oridonin attenuates TNBS-induced
post-inflammatory irritable bowel syndrome via PXR/NF-κB signaling.
Inflammation. 44:645–658. 2021.PubMed/NCBI View Article : Google Scholar
|
|
18
|
Yang Y, Liu Y, Wang Y, Chao Y, Zhang J,
Jia Y, Tie J and Hu D: Regulation of SIRT1 and its roles in
inflammation. Front Immunol. 13(831168)2022.PubMed/NCBI View Article : Google Scholar
|
|
19
|
Jia XM, Hao H, Zhang Q, Yang MX, Wang N,
Sun SL, Yang ZN, Jin YR, Wang J and Du YF: The bioavailability
enhancement and insight into the action mechanism of poorly soluble
natural compounds from co-crystals preparation: Oridonin as an
example. Phytomedicine. 122(155179)2024.PubMed/NCBI View Article : Google Scholar
|
|
20
|
Zhao G, Zhang T, Ma X, Jiang K, Wu H, Qiu
C, Guo M and Deng G: Oridonin attenuates the release of
pro-inflammatory cytokines in lipopolysaccharide-induced RAW264.7
cells and acute lung injury. Oncotarget. 8:68153–68164.
2017.PubMed/NCBI View Article : Google Scholar
|
|
21
|
Artursson P, Palm K and Luthman K: Caco-2
monolayers in experimental and theoretical predictions of drug
transport. Adv Drug Deliv Rev. 46:27–43. 2001.PubMed/NCBI View Article : Google Scholar
|
|
22
|
Sambuy Y, De Angelis I, Ranaldi G, Scarino
ML, Stammati A and Zucco F: The Caco-2 cell line as a model of the
intestinal barrier: Influence of cell and culture related factors
on Caco-2 cell functional characteristics. Cell Biol Toxicol.
21:1–26. 2005.PubMed/NCBI View Article : Google Scholar
|
